Breast Cancer Clinical Trials & Research at St. Joseph Health Medical Group

In the U.S., breast cancer is the second most common cancer in women after skin cancer. It can occur in both men and women. The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Breast cancer can also begin in the cells of the lobules and in other tissues in the breast. Invasive breast cancer is breast cancer that has spread from where it began in the ducts or lobules to surrounding tissue.

St. Joseph Health Medical Group is currently enrolling patients for the following breast cancer clinical trials:

Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (NCI BWEL)

Treatment agent: Health education program +/- weight loss intervention
PI: Thomas Stanton, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links: clinicaltrials.gov NCT No: NCT02750826

A Phase III, Randomized, Double-blind, Placebo Controlled Study of Adagloxad Simolenin (OBI-822)/OBI-821 Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients, defined as Residual Invasive Disease following Neoadjuvant Chemotherapy OR ≥ 4 Positive Axillary Nodes (JIT OBI-822)

Treatment agent: OBI-822/OBI-821
PI: Thomas Stanton, MD
Study Coordinator: Kim Young // Kimberly.Young@stjoe.org // (707) 521-3814
Resources and Links: clinicaltrials.gov NCT No: NCT03562637

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC trial.

Treatment agent: Asparin
PI: Thomas Stanton, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links: clinicaltrials.gov NCT No: NCT02927249

A Phase II, Multicenter, Randomized Study To Compare the Efficacy of Venetoclax Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor−Positive, Her2−Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Recurrence or Progression During or After Cdk4/6 Inhibitor Therapy (Roche Breast)

Treatment agent: Fulvestrant +/- venetoclax
PI: Thomas Stanton, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links: clinicaltrials.gov NCT No: NCT03584009

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (JIT Odonate)

Treatment agent: Tesetaxel +/- capecitabine
PI: Thomas Stanton, MD
Study Coordinator: Kim Young // Kimberly.Young@stjoe.org // (707) 521-3814
Resources and Links: clinicaltrials.gov NCT No: NCT03326674

Palbociclib (IBRANCE) in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study (POLARIS)

Treatment agent: N/A
PI: Thomas Stanton, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links: clinicaltrials.gov NCT No: NCT03280303

A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with Pembrolizumab (BriaCell Rollover)

Treatment agent: SV-BR-1-GM + Pembrolizumab
PI: Jarrod Holmes, MD
Study Coordinator: Sabine Ucik // Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links: clinicaltrials.gov NCT No: NCT03328026

Our Providers

Our Locations